Form 4: Enliven Therapeutics CEO Samuel Kintz Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Enliven Therapeutics' CEO, Samuel Kintz, sold 924 shares of common stock at a weighted average price of $30.0029, executed under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On October 18, 2024, Samuel Kintz, the President and CEO of Enliven Therapeutics, sold 924 shares of common stock.
- The sale was executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
- The shares were sold at a weighted average price of $30.0029, with individual trades ranging from $30.00 to $30.03.
- Following the transaction, Kintz indirectly owns 1,002,892 shares through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock sales by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by the CEO could have a minor negative impact on shareholder confidence, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| March 30, 2019 | Date of The Kintz & Egan Trust |
| June 26, 2023 | Date the Rule 10b5-1 trading plan was adopted |
| October 18, 2024 | Date of the stock sale transaction |
| October 22, 2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.